GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (NAS:ILMN) » Definitions » ROC (Joel Greenblatt) %

Illumina (Illumina) ROC (Joel Greenblatt) %

: -34.86% (As of Dec. 2023)
View and export this data going back to 2000. Start your Free Trial

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Illumina's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -34.86%.

The historical rank and industry rank for Illumina's ROC (Joel Greenblatt) % or its related term are showing as below:

ILMN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -222.91   Med: 73.96   Max: 133.65
Current: -56.94

During the past 13 years, Illumina's highest ROC (Joel Greenblatt) % was 133.65%. The lowest was -222.91%. And the median was 73.96%.

ILMN's ROC (Joel Greenblatt) % is ranked worse than
59.57% of 235 companies
in the Medical Diagnostics & Research industry
Industry Median: -15.21 vs ILMN: -56.94

Illumina's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Illumina ROC (Joel Greenblatt) % Historical Data

The historical data trend for Illumina's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.74 49.67 49.33 -222.91 -60.45

Illumina Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.69 -12.18 -14.38 -165.02 -34.86

Competitive Comparison

For the Diagnostics & Research subindustry, Illumina's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Illumina ROC (Joel Greenblatt) % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Illumina's ROC (Joel Greenblatt) % falls into.



Illumina ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(690 + 615 + 268) - (960 + 242 + 195)
=176

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(734 + 587 + 234) - (1009 + 252 + 223)
=71

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Illumina for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-596/( ( (1621 + max(176, 0)) + (1551 + max(71, 0)) )/ 2 )
=-596/( ( 1797 + 1622 )/ 2 )
=-596/1709.5
=-34.86 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Illumina  (NAS:ILMN) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Illumina ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Illumina's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Illumina (Illumina) Business Description

Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates about 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (about 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Executives
Aimee L Hoyt officer: SVP, Chief People Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jacob Thaysen director, officer: Chief Executive Officer 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Susan H Tousi officer: SVP Product Development 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Steven Barnard officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott B. Ullem director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Stephen P Macmillan director 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Andrew Teno director C/O FIR TREE INC., 55 WEST 46TH STREET, 29TH FLOOR, NEW YORK NY 10036
Alexander Aravanis officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott D Ericksen officer: VP, Chief Accounting Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Charles Dadswell officer: Sr VP & General Counsel 5200 ILLUMINA WAY, SAN DIEGO CA 92122
John Edward Frank officer: Chief Public Affairs Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Phillip G. Febbo officer: SVP Chief Medical Officer C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carissa Rollins officer: SVP, Chief Information Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Kevin Carl Pegels officer: Chief of Global Operations 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jay T Flatley officer: President & CEO 9885 TOWNE CENTRE DR, SAN DIEGO CA 92121

Illumina (Illumina) Headlines

From GuruFocus

Illumina Inc 2022 Investor Day Transcript

By GuruFocus Research 01-23-2024

Q4 2021 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Illumina Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Illumina Inc Inaugural ESG Investor Event Transcript

By GuruFocus Research 01-23-2024

Illumina Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024